Evidence map›Paper›PMID 36909845›Full record

ArticleFrontiers in microbiology2022

Real-time PCR has advantages over culture-based methods in identifying major airway bacterial pathogens in chronic obstructive pulmonary disease: Results from three clinical studies in Europe and North America.

Sonia Schoonbroodt, Jean-Laurent Ichanté, Sophie Boffé, Nathalie Devos, Jeanne-Marie Devaster, Laura Taddei, Simona Rondini, Ashwani Kumar Arora, Thierry Pascal, Ludovic Malvaux

3 registry-linked trialsFull text read
In one paragraph

Article in Frontiers in microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01360398 nacompletednot on this map

Contribution of Infectious Pathogens to Acute Respiratory Illness in Adults and Elderly

TypeinterventionalSponsorGlaxoSmithKlineRan2011 to 2014Enrolled127ConditionsRespiratory DisordersArmsBlood sample, Sputum sample, Nasopharyngeal swab, Urine sample, End tidal breath sample
NCT02075541 phase2completednot on this map

An Observer-blind Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Investigational Vaccine GSK2838504A When Administered to Chronic Obstructive Pulmonary Disease (COPD) Patients

TypeinterventionalSponsorGlaxoSmithKlineRan2014 to 2017Enrolled145ConditionsRespiratory DisordersArmsNTHi-10-AS01E, NaCl Placebo
NCT03281876 phase2completednot on this map

An Observer-blind Study to Evaluate the Efficacy, Safety, Reactogenicity and Immunogenicity of the GSK Biologicals' Investigational Vaccine GSK3277511A When Administered to COPD Patients

TypeinterventionalSponsorGlaxoSmithKlineRan2017 to 2020Enrolled606ConditionsRespiratory DisordersArmsNTHi Mcat investigational vaccine (GSK3277511A), Placebo
3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Breathe (Sheffield, England) · 2026
    Review
  3. Article
  4. Article
  5. Observational
  6. Review
  7. Review
  8. Detection ofNarra J · 2024
    Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Sonia SchoonbroodtGSK, Rixensart, Belgium.
Jean-Laurent IchantéGSK, Rixensart, Belgium.
Sophie BofféGSK, Wavre, Belgium.
Nathalie DevosGSK, Rixensart, Belgium.
Jeanne-Marie DevasterGSK, Rixensart, Belgium.
Laura TaddeiGSK, Siena, Italy.
Simona RondiniGSK, Siena, Italy.
Ashwani Kumar AroraGSK, Siena, Italy.
Thierry PascalGSK, Wavre, Belgium.
Ludovic MalvauxGSK, Wavre, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: We compared the performance of real-time PCR with culture-based methods for identifying bacteria in sputum samples from patients with chronic obstructive pulmonary disease (COPD) in three studies. Methods: This was an exploratory analysis of sputum samples collected during an observational study of 127 patients (AERIS; NCT01360398), phase 2 study of 145 patients (NTHI-004; NCT02075541), and phase 2b study of 606 patients (NTHI-MCAT-002; NCT03281876). Bacteria were identified by culture-based microbiological methods in local laboratories using fresh samples or by real-time PCR in a central laboratory using frozen samples. Results: Bacterial detection results from both culture-based and PCR assays were available from 2,293 samples from AERIS, 974 from the NTHI-004 study, and 1736 from the NTHI-MCAT-002 study. Quantitative real-time PCR (qPCR) showed higher positivity rates than culture for Discussion: Real-time PCR on frozen sputum samples has enhanced sensitivity and specificity over culture-based methods, supporting its use for the identification of common respiratory bacterial species in patients with COPD.

Indexed as

bacterial identificationchronic obstructive pulmonary diseasecultureHaemophilus influenzaeMoraxella catarrhalisPCRsensitivityStreptococcus pneumoniae

Identifiers

PMID36909845
PMCPMC10000296

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read32
identifiers read3
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.